Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: The present invention relates to an oral thin film, comprising at least one layer which contains at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and to the use of such an oral thin film as a medicament.

Abstract: The present invention relates to a multi-layer oral thin film comprising a matrix layer, which contains at least one polymer and at least one pharmaceutically active agent, and at least one backing layer, wherein the at least one backing layer comprises at least one polyethylene glycol, to a method for production of the oral thin film, and to the use of such an oral thin film as a medicament.

Abstract: The present invention relates to an oral thin film comprising at least one matrix polymer and at least one active pharmaceutical ingredient, wherein the at least one active pharmaceutical ingredient is an acid or a base, characterised in that the at least one active pharmaceutical ingredient is present in the form of a mixture which comprises the at least one active pharmaceutical ingredient both in the form of the free acid or base and in the form of a pharmaceutically acceptable salt, a method for producing said oral thin film, and the use of such an oral thin film as a medicament.

Abstract: The present disclosure relates to a multi-layer oral thin film comprising a first and a second matrix layer, which each contain at least one polymer, and a separation layer located between the first and the second matrix layer, wherein the separation layer comprises at least one polyethylene glycol, to a method for production of the oral thin film, and to the use thereof as a medicament.

Abstract: The present invention relates to a method for producing a multi-layer oral thin film comprising the steps of a) providing a solution, an emulsion, a foam or a suspension comprising at least one first polymer, b) processing the solution, the emulsion, the foam or the suspension from step a) in order to obtain a polymer film, c) applying a powder comprising at least one second substance, which preferably differs from the first polymer, to the polymer film, and d) forming a composite between the polymer film and the powder applied in step c), to a multi-layer oral thin film obtainable by this method, and to the use of a multi-layer oral thin film obtainable by this method as a medicament.

Abstract: The present invention relates to a multi-layer thin film comprising at least two layers arranged one on top of the other which each comprise at least one polymer, these at least two layers being connected to one another by at least one stitched seam using at least one thread, and to a method for producing such a thin film and to the use thereof as a medicament.

Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: The invention relates to an oral thin film, comprising a polymer matrix and ulipristal acetate as an active agent, wherein ulipristal acetate is dispersed in the polymer matrix and the polymer matrix is a matrix of water-soluble polymer selected from poly(ethylene oxide), poly(vinyl alcohol) or hydroxypropyl methylcellulose. The oral thin film is suitable as emergency contraceptive and can be administered in the oral cavity without water. It quickly disintegrates in the oral cavity wherein the active agent ulipristal acetate is mainly swallowed in undissolved form and absorbed into the gastrointestinal tract.

Abstract: The invention relates to an oral thin film, comprising a polymer matrix and at least one water-insoluble, particulate active pharmaceutical ingredient dispersed in the polymer matrix, wherein the matrix polymer is poly(ethylene oxide) having a melting point of at least 55° C., the amount of poly(ethylene oxide) having a melting point of at least 55° C. is at least 40% by weight, based on the total weight of the oral thin film, and wherein the oral thin film is obtainable by a process comprising the steps of: a) preparing a suspension comprising the matrix polymer, the at least one water-insoluble, particulate active pharmaceutical ingredient and a solvent which s water or a mixture of water and one or more organic solvents, b) casting the suspension obtained on a support or in a mold, and c) drying the suspension at a temperature above the melting temperature of the poly(ethylene oxide).

Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: There is disclosed a composition comprising self-assembled nano-particles, the nano-particles comprising dendrimers having a phthalocyanine covalently bound to the periphery thereof. The composition is useful in the therapy and/or diagnosis and/or therapy monitoring and/or theranostics of a lesion of a tissue.